Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1987 Mar;55(3):547–554. doi: 10.1128/iai.55.3.547-554.1987

Antipyretic activity of a human immunoglobulin preparation for intravenous use in an experimental model of fever in rabbits.

M Iwata, T Shimozato, H Tokiwa, E Tsubura
PMCID: PMC260371  PMID: 3493219

Abstract

In an effort to elucidate the reason that fever in patients with severe bacterial infections subsided in some cases after the administration of human immunoglobulin preparations for intravenous use (IGIVs), we focused our attention on the antipyretic activity of IGIVs by investigating experimentally produced pyrexia in rabbits with Escherichia coli-derived lipopolysaccharide (LPS). Although little difference in antibody titers against the antigens composing molecules of LPS was found among the IGIVs that were used, IGIVs treated at pH 4 were demonstrated to inhibit a strongly LPS-induced second-phase febrile response, whereas the inhibitory effect of sulfonated and pepsin-treated IGIVs was weak. In vitro experiments on interleukin-1 production by rabbit macrophages stimulated with LPS, silica gel or latex beads and on rosette formation showed that these functions of the cells were also inhibited by IGIVs. The in vivo antipyretic activity and the results of the two in vitro experiments correlated closely. The inhibitory potency decreased in the following order: immunoglobulin G (IgG) treated at pH4, sulfonated IgG, and pepsin-treated IgG. Thus, it is possible that the subsidence of LPS-induced fever by IGIVs was mediated by inhibition of interleukin 1 production by means of binding of IgG to macrophages via an Fc receptor. Results of this study also indicated the importance of the structural integrity of the Fc portion of the IgG contained in the IGIVs to bind with its receptor on the macrophage so as to influence the various functions carried out by the cell.

Full text

PDF
547

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Diamond B., Bloom B. R., Scharff M. D. The Fc receptors of primary and cultured phagocytic cells studied with homogeneous antibodies. J Immunol. 1978 Oct;121(4):1329–1333. [PubMed] [Google Scholar]
  2. Dinarello C. A. An update on human interleukin-1: from molecular biology to clinical relevance. J Clin Immunol. 1985 Sep;5(5):287–297. doi: 10.1007/BF00918247. [DOI] [PubMed] [Google Scholar]
  3. Dinarello C. A. Interleukin-1. Rev Infect Dis. 1984 Jan-Feb;6(1):51–95. doi: 10.1093/clinids/6.1.51. [DOI] [PubMed] [Google Scholar]
  4. Dinarello C. A., Wolff S. M. Molecular basis of fever in humans. Am J Med. 1982 May;72(5):799–819. doi: 10.1016/0002-9343(82)90548-4. [DOI] [PubMed] [Google Scholar]
  5. Fernandes P. M., Lundblad J. L. Preparation of a stable intravenous gamma-globulin: process design and scale-up. Vox Sang. 1980 Aug;39(2):101–112. doi: 10.1111/j.1423-0410.1980.tb01844.x. [DOI] [PubMed] [Google Scholar]
  6. Gery I., Gershon R. K., Waksman B. H. Potentiation of the T-lymphocyte response to mitogens. I. The responding cell. J Exp Med. 1972 Jul 1;136(1):128–142. doi: 10.1084/jem.136.1.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Greisman S. E., Woodward C. L. Mechanisms of endotoxin tolerance. VII. The role of the liver. J Immunol. 1970 Dec;105(6):1468–1476. [PubMed] [Google Scholar]
  8. Jungi T. W., Barandun S. Estimation of the degree of opsonization of homologous erythrocytes by IgG for intravenous and intramuscular use. Vox Sang. 1985;49(1):9–19. doi: 10.1111/j.1423-0410.1985.tb00762.x. [DOI] [PubMed] [Google Scholar]
  9. Masuho Y., Tomibe K., Watanabe T., Fukumoto Y. Development of an intravenous gamma-globulin with Fc activities. II. Reconversion of S-sulfonated human gamma-globulin into the original gamma-globulin. Vox Sang. 1977;32(5):290–295. doi: 10.1111/j.1423-0410.1977.tb00648.x. [DOI] [PubMed] [Google Scholar]
  10. Matsumoto K., Masaoka T., Nakamura T., Shimada K., Urushizaki I., Kogo Y., Saito A., Tomizawa M., Nakayana I., Mikuni C. [Therapeutic evaluation of combination therapy with IG-100, pH4-treated human immunoglobulin preparation for i.v. administration, and antibiotics against severe infections. The Society for Clinical Investigation on IG-100]. Kansenshogaku Zasshi. 1984 Oct;58(10):1001–1024. doi: 10.11150/kansenshogakuzasshi1970.58.1001. [DOI] [PubMed] [Google Scholar]
  11. Murphy P. A., Simon P. L., Willoughby W. F. Endogenous pyrogens made by rabbit peritoneal exudate cells are identical with lymphocyte-activating factors made by rabbit alveolar macrophages. J Immunol. 1980 May;124(5):2498–2501. [PubMed] [Google Scholar]
  12. Oppenheim J. J., Stadler B. M., Siraganian R. P., Mage M., Mathieson B. Lymphokines: their role in lymphocyte responses. Properties of interleukin 1. Fed Proc. 1982 Feb;41(2):257–262. [PubMed] [Google Scholar]
  13. Parish C. R., Hayward J. A. The lymphocyte surface. I. Relation between Fc receptors, C'3 receptors and surface immunoglobulin. Proc R Soc Lond B Biol Sci. 1974 Aug 27;187(1086):47–63. doi: 10.1098/rspb.1974.0060. [DOI] [PubMed] [Google Scholar]
  14. Römer J., Morgenthaler J. J., Scherz R., Skvaril F. Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content. Vox Sang. 1982 Feb;42(2):62–73. doi: 10.1159/000460850. [DOI] [PubMed] [Google Scholar]
  15. Römer J., Späth P. J., Skvaril F., Nydegger U. E. Characterization of various immunoglobulin preparations for intravenous application. II. Complement activation and binding to staphylococcus protein A. Vox Sang. 1982 Feb;42(2):74–80. doi: 10.1159/000460851. [DOI] [PubMed] [Google Scholar]
  16. SCHULTZE H. E., SCHWICK G. [On new possibilities of intravenous gamma globulin administration]. Dtsch Med Wochenschr. 1962 Aug 24;87:1643–passim. doi: 10.1055/s-0028-1113997. [DOI] [PubMed] [Google Scholar]
  17. Schreiber J. R., Barrus V. A., Siber G. R. Decreased protective efficacy of reduced and alkylated human immune serum globulin in experimental infection with Haemophilus influenzae type b. Infect Immun. 1985 Jan;47(1):142–148. doi: 10.1128/iai.47.1.142-148.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sgouris J. T. The preparation of plasmin treated immune serum globulin for intravenous use. Vox Sang. 1967 Jul;13(1):71–84. [PubMed] [Google Scholar]
  19. Skarnes R. C., Brown S. K., Hull S. S., McCracken J. A. Role of prostaglandin E in the biphasic fever response to endotoxin. J Exp Med. 1981 Oct 1;154(4):1212–1224. doi: 10.1084/jem.154.4.1212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Stephan W. Undegraded human immunoglobulin for intravenous use. Vox Sang. 1975;28(6):422–437. doi: 10.1111/j.1423-0410.1975.tb02791.x. [DOI] [PubMed] [Google Scholar]
  21. Vos J. G., Buys J., Hanstede J. G., Hagenaars A. M. Comparison of enzyme-linked immunosorbent assay and passive hemagglutination method for quantification of antibodies to lipopolysaccharide and tetanus toxoid in rats. Infect Immun. 1979 Jun;24(3):798–803. doi: 10.1128/iai.24.3.798-803.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Which is the factual basis, in theory and clinical practice, for the use of intravenous gammaglobulin in the treatment of severe bacterial infections? Vox Sang. 1979;37(2):116–128. [PubMed] [Google Scholar]
  23. van Furth R., Leijh P. C., Klein F. Correlation between opsonic activity for various microorganisms and composition of gammaglobulin preparations for intravenous use. J Infect Dis. 1984 Apr;149(4):511–517. doi: 10.1093/infdis/149.4.511. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES